These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10087650)

  • 41. IL-12 in autoimmunity.
    Caspi RR
    Clin Immunol Immunopathol; 1998 Jul; 88(1):4-13. PubMed ID: 9683544
    [No Abstract]   [Full Text] [Related]  

  • 42. Low dose TGF-beta attenuates IL-12 responsiveness in murine Th cells.
    Gorham JD; Güler ML; Fenoglio D; Gubler U; Murphy KM
    J Immunol; 1998 Aug; 161(4):1664-70. PubMed ID: 9712029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-12 as an adjuvant for cell-mediated immunity.
    Scott P; Trinchieri G
    Semin Immunol; 1997 Oct; 9(5):285-91. PubMed ID: 9327523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease.
    Seder RA; Kelsall BL; Jankovic D
    J Immunol; 1996 Oct; 157(7):2745-8. PubMed ID: 8816374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application.
    Zitvogel L; Lotze MT
    Res Immunol; 1995; 146(7-8):628-38. PubMed ID: 8839171
    [No Abstract]   [Full Text] [Related]  

  • 46. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system.
    Zhang GX; Gran B; Yu S; Li J; Siglienti I; Chen X; Kamoun M; Rostami A
    J Immunol; 2003 Feb; 170(4):2153-60. PubMed ID: 12574388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor models to investigate the therapeutic efficiency of immunomodulators.
    Talmadge E; Lenz BF; Collins MS; Uithoven KA; Schneider MA; Adams JS; Pearson JW; Agee WJ; Fox RE; Oldham RK
    Behring Inst Mitt; 1984 May; (74):219-29. PubMed ID: 6477354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization.
    Ha SJ; Kim DJ; Baek KH; Yun YD; Sung YC
    J Immunol; 2004 Jan; 172(1):525-31. PubMed ID: 14688363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice.
    Mandpe AH; Tsung K; Norton JA
    Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):786-92. PubMed ID: 12874083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development.
    Wenner CA; Güler ML; Macatonia SE; O'Garra A; Murphy KM
    J Immunol; 1996 Feb; 156(4):1442-7. PubMed ID: 8568246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IL-12p40 and IL-18 in crescentic glomerulonephritis: IL-12p40 is the key Th1-defining cytokine chain, whereas IL-18 promotes local inflammation and leukocyte recruitment.
    Kitching AR; Turner AL; Wilson GR; Semple T; Odobasic D; Timoshanko JR; O'Sullivan KM; Tipping PG; Takeda K; Akira S; Holdsworth SR
    J Am Soc Nephrol; 2005 Jul; 16(7):2023-33. PubMed ID: 15888563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antitumor activities of IL-12 and mechanisms of action.
    Shurin MR; Esche C; Péron JM; Lotze MT
    Chem Immunol; 1997; 68():153-74. PubMed ID: 9329221
    [No Abstract]   [Full Text] [Related]  

  • 53. A novel function of IL-12p40 as a chemotactic molecule for macrophages.
    Ha SJ; Lee CH; Lee SB; Kim CM; Jang KL; Shin HS; Sung YC
    J Immunol; 1999 Sep; 163(5):2902-8. PubMed ID: 10453037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease.
    Schmidt C; Marth T; Wittig BM; Hombach A; Abken H; Stallmach A
    Pathobiology; 2002-2003; 70(3):177-83. PubMed ID: 12571423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling.
    Nishikomori R; Gurunathan S; Nishikomori K; Strober W
    J Immunol; 2001 Jun; 166(11):6776-83. PubMed ID: 11359836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes.
    Wynn TA; Sher A
    Res Immunol; 1995; 146(7-8):582-90. PubMed ID: 8839165
    [No Abstract]   [Full Text] [Related]  

  • 57. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS; Penichet ML; Morrison SL
    J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-12 (IL-12)-driven alloimmune responses in vitro and in vivo: requirement for beta1 subunit of the IL-12 receptor.
    Piccotti JR; Li K; Chan SY; Eichwald EJ; Bishop DK
    Transplantation; 1999 Jun; 67(11):1453-60. PubMed ID: 10385085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Highlights of the international symposium on immunotherapeutic prospects of infectious diseases.
    Masihi KN
    Nat Immun Cell Growth Regul; 1991; 10(4):185-95. PubMed ID: 1896053
    [No Abstract]   [Full Text] [Related]  

  • 60. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.
    Stallmach A; Marth T; Weiss B; Wittig BM; Hombach A; Schmidt C; Neurath M; Zeitz M; Zeuzem S; Abken H
    Gut; 2004 Mar; 53(3):339-45. PubMed ID: 14960512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.